sotalol has been researched along with Coronary Disease in 56 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of sotalol depending on the magnitude of changes in adrenal responsiveness and autonomic nervous system tone in patients with paroxysmal atrial fibrillation (AF)." | 7.83 | [A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone]. ( Afanasyev, SA; Batalov, RE; Borisova, EV; Kisteneva, IV; Popov, SV; Rebrova, TY, 2016) |
| "This study was designed to determine the hemodynamic effects of the class III antiarrhythmic agent d-sotalol in acute ischemic heart failure at concentrations that prolong ventricular repolarization." | 7.68 | Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs. ( Kløw, NE; Mortensen, E; Refsum, H; Tande, PM, 1992) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 7.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 7.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 7.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| "The effects of hypoxia on the actions of dl-sotalol 10(-4) mol ." | 7.67 | Interaction of the effects of hypoxia, substrate depletion, acidosis and hyperkalaemia on the class III antiarrhythmic properties of sotalol. ( Alexopoulos, D; Cobbe, SM; Manley, BS, 1985) |
| "Sotalol was especially effective in reducing high grade arrhythmias (couplets, "R on T" VPCs)." | 5.27 | Long-term sotalol therapy in patients with ventricular arrhythmias. ( Mary-Rabine, L; Soumagne, D; Stiels, B, 1986) |
| "A distinct phase of ventricular arrhythmias was evident about 10 to 30 min after ligation." | 5.27 | Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP. ( Gihwala, D; Hamm, CW; Muller, CA; Opie, LH; Peisach, M, 1986) |
| "Sotalol is a non-selective beta-adrenergic blocking agent with class III antiarrhythmic properties." | 5.27 | The effect of sotalol on exercise-induced ventricular arrhythmias. ( Glogar, D; Petzl, DH; Probst, P; Schuster, E, 1988) |
| "To evaluate the efficacy of sotalol depending on the magnitude of changes in adrenal responsiveness and autonomic nervous system tone in patients with paroxysmal atrial fibrillation (AF)." | 3.83 | [A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone]. ( Afanasyev, SA; Batalov, RE; Borisova, EV; Kisteneva, IV; Popov, SV; Rebrova, TY, 2016) |
| "Implantable cardioverter-defibrillators (ICDs) and d,l-sotalol are widely used to treat ventricular tachyarrhythmia and ventricular fibrillation (VT/VF)." | 3.69 | Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Hammel, D; Haverkamp, W, 1996) |
| "This study was designed to determine the hemodynamic effects of the class III antiarrhythmic agent d-sotalol in acute ischemic heart failure at concentrations that prolong ventricular repolarization." | 3.68 | Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs. ( Kløw, NE; Mortensen, E; Refsum, H; Tande, PM, 1992) |
| "The aim of this study was to compare the effects of d- and dl-sotalol on the ventricular fibrillation threshold (VFT) and the effective refractory period (VERP) in anaesthetized cats subjected to coronary artery occlusion." | 3.68 | Comparative antifibrillatory effects of d- and dl-sotalol in normal and ischaemic ventricular muscle of the cat. ( Gwilt, M; Kane, KA; Kwan, YW; Solca, AM; Wadsworth, RM, 1990) |
| "To assess the antiarrhythmic efficacy of oral d,l-sotalol, 68 patients with sustained monomorphic ventricular tachycardia (SMVT) (n = 62) or ventricular fibrillation (VF) (n = 6) were studied by programmed ventricular stimulation (PVS)." | 3.68 | Sotalol in patients with life-threatening ventricular tachyarrhythmias. ( Klein, H; Lichtlen, P; Trappe, HJ, 1990) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 3.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 3.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| "The effects of hypoxia on the actions of dl-sotalol 10(-4) mol ." | 3.67 | Interaction of the effects of hypoxia, substrate depletion, acidosis and hyperkalaemia on the class III antiarrhythmic properties of sotalol. ( Alexopoulos, D; Cobbe, SM; Manley, BS, 1985) |
| "In patients prone to sudden cardiac death, there is a reduction in TWA amplitude following the administration of antiadrenergic drugs." | 2.70 | Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. ( Grönefeld, G; Hohnloser, SH; Klingenheben, T; Li, YG, 2001) |
| " The chronic use of beta adrenergic blockers (BAB) has been associated with reductions in HDL-cholesterol (HDL-C) and increases in triglycerides (TG)." | 2.66 | Alterations in plasma lipids consequent to endurance training and beta-blockade. ( Ewy, GA; Freund, BJ; Hartzell, AA; Jilka, SM; Joyner, MJ; Morton, AR; Stanforth, PR; Wilmore, JH, 1989) |
| "Amiodarone has been demonstrated to be an important and effective antiarrhythmic agent, as has sotalol." | 2.38 | Empiric use of amiodarone and sotalol. ( Nora, M; Zipes, DP, 1993) |
| "Slowing of ventricular tachycardia rate and changes in morphology may have implications in patients receiving implantable cardioverter-defibrillators or those undergoing ablative procedures." | 1.29 | Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy. ( Borggrefe, M; Breithardt, G; Chen, X; Haverkamp, W; Hindricks, G; Lubinski, A; Reisinger, J; Shenasa, M, 1995) |
| "Sotalol is a class III antiarrhythmic drug with additional beta-blocker activity that has been shown to be effective in supraventricular and ventricular arrhythmias." | 1.29 | Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. ( Boone, J; Kerr, CR; Mohama, R; Yeung-Lai-Wah, JA; Young, GD, 1994) |
| "Chronic treatment of heart failure patients with beta-adrenoceptor antagonists leads to an up-regulation of cardiac beta-adrenoceptors, but in a subtype-selective fashion: beta 1-selective antagonists increase only cardiac beta 1-adrenoceptors, whereas non-selective antagonists increase both beta 1- and beta 2-adrenoceptors." | 1.28 | Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. ( Borst, HG; Brodde, OE; Maier, W; Michel, MC; Zerkowski, HR, 1989) |
| "Sotalol was especially effective in reducing high grade arrhythmias (couplets, "R on T" VPCs)." | 1.27 | Long-term sotalol therapy in patients with ventricular arrhythmias. ( Mary-Rabine, L; Soumagne, D; Stiels, B, 1986) |
| "A distinct phase of ventricular arrhythmias was evident about 10 to 30 min after ligation." | 1.27 | Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP. ( Gihwala, D; Hamm, CW; Muller, CA; Opie, LH; Peisach, M, 1986) |
| "Sotalol is a non-selective beta-adrenergic blocking agent with class III antiarrhythmic properties." | 1.27 | The effect of sotalol on exercise-induced ventricular arrhythmias. ( Glogar, D; Petzl, DH; Probst, P; Schuster, E, 1988) |
| "Correspondingly, ventricular arrhythmias and fibrillation were almost completely prevented by metoprolol, d-sotalol or verapamil, but increased by lidocaine." | 1.27 | Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion. ( Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987) |
| "Resistance across the stenosis decreased significantly (p less than 0." | 1.26 | Changes in ischemic blood flow distribution and dynamic severity of a coronary stenosis induced by beta blockade in the canine heart. ( Buck, JD; Gross, GJ; Hardman, HF; Warltier, DC, 1981) |
| "Occlusion of the LAD artery produced arrhythmia in all of the animals, with 39% developing ventricular fibrillation (VF)." | 1.25 | Influence of the adrenal medulla on cardiac rhythm disturbances following acute coronary artery occlusions. ( Kelliher, GJ; Roberts, J; Widmer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (51.79) | 18.7374 |
| 1990's | 21 (37.50) | 18.2507 |
| 2000's | 5 (8.93) | 29.6817 |
| 2010's | 1 (1.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borisova, EV | 1 |
| Afanasyev, SA | 1 |
| Rebrova, TY | 1 |
| Kisteneva, IV | 1 |
| Batalov, RE | 1 |
| Popov, SV | 1 |
| Mátyus, P | 1 |
| Varga, I | 1 |
| Rettegi, T | 1 |
| Simay, A | 1 |
| Kállay, N | 1 |
| Károlyházy, L | 1 |
| Kocsis, A | 1 |
| Varró, A | 1 |
| Pénzes, I | 1 |
| Papp, JG | 2 |
| Johansson, SR | 1 |
| McCall, M | 1 |
| Wilhelmsson, C | 1 |
| Vedin, JA | 1 |
| Buck, JD | 2 |
| Hardman, HF | 3 |
| Warltier, DC | 3 |
| Gross, GJ | 3 |
| Frishman, WH | 1 |
| Furberg, CD | 1 |
| Friedewald, WT | 1 |
| Burckhardt, D | 1 |
| Pfisterer, M | 1 |
| Hoffmann, A | 1 |
| Burkart, F | 1 |
| Emmenegger, H | 1 |
| Jost, M | 1 |
| Bolli, P | 1 |
| Buehler, FR | 1 |
| Lamping, KG | 1 |
| Izumi, T | 1 |
| Sakai, K | 2 |
| Abiko, Y | 3 |
| Henderson, A | 1 |
| Errington, J | 1 |
| Martínez-Rubio, A | 1 |
| Shenasa, M | 2 |
| Chen, X | 2 |
| Wichter, T | 1 |
| Breithardt, G | 3 |
| Borggrefe, M | 3 |
| Reisinger, J | 1 |
| Lubinski, A | 1 |
| Hindricks, G | 2 |
| Haverkamp, W | 3 |
| Young, GD | 1 |
| Kerr, CR | 1 |
| Mohama, R | 1 |
| Boone, J | 1 |
| Yeung-Lai-Wah, JA | 1 |
| Höher, M | 1 |
| Axmann, J | 1 |
| Eggeling, T | 1 |
| Kochs, M | 1 |
| Weismüller, P | 1 |
| Hombach, V | 1 |
| Nora, M | 1 |
| Zipes, DP | 1 |
| Böcker, D | 1 |
| Block, M | 2 |
| Hammel, D | 1 |
| Gautam, CS | 1 |
| Sharma, PL | 1 |
| Pandhi, P | 1 |
| Montero, M | 1 |
| Schmitt, C | 1 |
| Neuzner, J | 1 |
| Bahawar, H | 1 |
| Berkowitsch, A | 1 |
| Michel, U | 1 |
| Schlepper, M | 1 |
| Pitschner, HF | 1 |
| Giorgberidze, I | 1 |
| Saksena, S | 1 |
| Krol, RB | 1 |
| Munsif, AN | 1 |
| Kolettis, T | 1 |
| Mathew, P | 1 |
| Varanasi, S | 1 |
| Prakash, A | 1 |
| Delfaut, P | 1 |
| Lewis, CB | 1 |
| Kovoor, P | 2 |
| Eipper, V | 1 |
| Byth, K | 2 |
| Cooper, MJ | 2 |
| Uther, JB | 2 |
| Ross, DL | 2 |
| Owens, P | 1 |
| O'Brien, E | 1 |
| Naccarella, F | 1 |
| Rolli, A | 1 |
| Carboni, A | 1 |
| Finardi, A | 1 |
| Aurier, E | 1 |
| Favaro, L | 1 |
| Contini, S | 1 |
| Gherli, T | 1 |
| Caponi, D | 1 |
| Maranga, SS | 1 |
| Lepera, G | 1 |
| Bartoletti, A | 1 |
| Pruvot, E | 1 |
| Thonet, G | 1 |
| Vesin, JM | 1 |
| van-Melle, G | 1 |
| Seidl, K | 1 |
| Schmidinger, H | 1 |
| Brachmann, J | 1 |
| Jung, W | 1 |
| Hoffmann, E | 1 |
| Tavernier, R | 1 |
| Podczeck, A | 1 |
| Fromer, M | 1 |
| Yung, A | 1 |
| Eipper, VE | 1 |
| Aggarwal, A | 1 |
| Klingenheben, T | 1 |
| Grönefeld, G | 1 |
| Li, YG | 1 |
| Hohnloser, SH | 1 |
| Spear, JF | 1 |
| Moore, EN | 1 |
| Ichihara, K | 2 |
| Ichihara, M | 1 |
| Kelliher, GJ | 1 |
| Widmer, C | 1 |
| Roberts, J | 1 |
| Mortensen, E | 1 |
| Tande, PM | 1 |
| Kløw, NE | 1 |
| Refsum, H | 1 |
| Kwan, YW | 1 |
| Solca, AM | 1 |
| Gwilt, M | 1 |
| Kane, KA | 1 |
| Wadsworth, RM | 1 |
| Hoffmeister, HM | 1 |
| Müller, S | 1 |
| Seipel, L | 1 |
| Németh, M | 1 |
| Trappe, HJ | 2 |
| Klein, H | 2 |
| Lichtlen, P | 1 |
| Sano, T | 1 |
| Sugiyama, S | 1 |
| Taki, K | 1 |
| Hanaki, Y | 1 |
| Shimada, Y | 1 |
| Ozawa, T | 1 |
| Hicks, MN | 1 |
| Cobbe, SM | 4 |
| Mary-Rabine, L | 1 |
| Soumagne, D | 1 |
| Stiels, B | 1 |
| Brodde, OE | 1 |
| Zerkowski, HR | 1 |
| Borst, HG | 1 |
| Maier, W | 1 |
| Michel, MC | 1 |
| Morton, AR | 1 |
| Stanforth, PR | 1 |
| Freund, BJ | 1 |
| Joyner, MJ | 1 |
| Jilka, SM | 1 |
| Hartzell, AA | 1 |
| Ewy, GA | 1 |
| Wilmore, JH | 1 |
| Ginestes, J | 1 |
| Gough, WB | 1 |
| el-Sherif, N | 1 |
| Kuchar, DL | 1 |
| Garan, H | 1 |
| Venditti, FJ | 1 |
| Finkelstein, D | 1 |
| Rottman, JN | 1 |
| McComb, J | 1 |
| McGovern, BA | 1 |
| Ruskin, JN | 1 |
| Harvengt, C | 1 |
| Desager, JP | 1 |
| Heller, F | 1 |
| Hulhoven, R | 1 |
| Muller, CA | 1 |
| Opie, LH | 1 |
| Hamm, CW | 1 |
| Peisach, M | 1 |
| Gihwala, D | 1 |
| Way, BP | 1 |
| Forfar, JC | 1 |
| Kopelman, HA | 1 |
| Woosley, RL | 1 |
| Lee, JT | 1 |
| Roden, DM | 1 |
| Echt, DS | 1 |
| Petzl, DH | 1 |
| Probst, P | 1 |
| Glogar, D | 1 |
| Schuster, E | 1 |
| Thale, J | 1 |
| Gülker, H | 1 |
| Lichtlen, PR | 1 |
| Lynch, JJ | 1 |
| Coskey, LA | 1 |
| Montgomery, DG | 1 |
| Lucchesi, BR | 1 |
| Manley, BS | 2 |
| Alexopoulos, D | 2 |
| Khan, MI | 2 |
| Hamilton, JT | 2 |
| Manning, GW | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for sotalol and Coronary Disease
| Article | Year |
|---|---|
Novel antiarrhythmic compounds with combined class IB and class III mode of action.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Coronary Disease; Delayed Rectifier Potassium Ch | 2004 |
Beta-adrenergic blockade for survivors of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alprenolol; Arrhythmias, Cardiac; Clinical Trials as Topic; Coron | 1984 |
Empiric use of amiodarone and sotalol.
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Coronary Disease; Death, Sudden, Cardiac; Heart Diseases; | 1993 |
9 trials available for sotalol and Coronary Disease
| Article | Year |
|---|---|
Duration of action of beta blockers.
Topics: Adrenergic beta-Antagonists; Adult; Alprenolol; Atenolol; Blood Pressure; Coronary Disease; Heart Ra | 1980 |
Beta-adrenergic blockade for survivors of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alprenolol; Arrhythmias, Cardiac; Clinical Trials as Topic; Coron | 1984 |
Effects of the beta-adrenoceptor-blocking agent Sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease. A placebo-controlled, double-blind cross-over study.
Topics: Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Meth | 1983 |
Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Confounding Factors, Epidemiologic; Coronary Disease; Deat | 1997 |
Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Disease; Cross-Over Studies; Electrocardiography; | 1999 |
Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Cause of Death; Coronary Disease; Death, | 2001 |
Alterations in plasma lipids consequent to endurance training and beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Coronary Disease; Humans; Lipids; Male; Physical Educa | 1989 |
Comparison of the effects of chronic oral therapy with atenolol and sotalol on ventricular monophasic action potential duration and effective refractory period.
Topics: Action Potentials; Administration, Oral; Aged; Atenolol; Clinical Trials as Topic; Coronary Disease; | 1988 |
Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
Topics: Administration, Oral; Aged; Cardiac Pacing, Artificial; Clinical Trials as Topic; Coronary Disease; | 1988 |
45 other studies available for sotalol and Coronary Disease
| Article | Year |
|---|---|
[A change in adrenal responsiveness in sotalol-treated patients with paroxysmal atrial fibrillation depending on autonomic nervous system tone].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Autonomic Nervous System; Coronary Disease; | 2016 |
Changes in ischemic blood flow distribution and dynamic severity of a coronary stenosis induced by beta blockade in the canine heart.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Constriction, Pathologic; Coronary Circulation | 1981 |
Effects of three bradycardiac drugs on regional myocardial blood flow and function in areas distal to a total or partial coronary occlusion in dogs.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Collateral Circulation; Coronary Circulation; Coron | 1984 |
Effect of sotalol on ischemic myocardial pH in the dog heart.
Topics: Animals; Blood Pressure; Coronary Disease; Dogs; Female; Heart Rate; Hydrogen-Ion Concentration; Mal | 1982 |
Sudden versus gradual withdrawal of sotalol in ambulant patients with ischaemic heart disease.
Topics: Angina Pectoris; Blood Pressure; Coronary Disease; Heart Rate; Humans; Hypertension; Risk; Sotalol; | 1982 |
Effects of sotalol and vagal stimulation on ischemic myocardial blood flow distribution in the canine heart.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Dogs; Electric Stimulation; Female; | 1981 |
Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease.
Topics: Amiodarone; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; Cohort Studies; Coronary Disea | 1994 |
Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography | 1995 |
Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease.
Topics: Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrophysiology; Female; Humans; Male; Middle | 1994 |
Beat-to-beat variability of ventricular late potentials in the unaveraged high resolution electrocardiogram--effects of antiarrhythmic drugs.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Coronary Disease; Electroc | 1993 |
Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease.
Topics: Administration, Oral; Case-Control Studies; Combined Modality Therapy; Coronary Disease; Defibrillat | 1996 |
Differential effect of selected antiarrhythmic drugs on coronary artery ligation-induced ventricular arrhythmias on the right or left sides.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Disease Models, Animal; Dogs; Female; Ligation; M | 1995 |
Recording of transmembrane action potentials in chronic ischemic heart disease and dilated cardiomyopathy and the effects of the new class III antiarrhythmic agents D-sotalol and dofetilide.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Coronary Disease; Heart; Heart Ventricles; Humans; In Vitr | 1996 |
Clinical predictors of defibrillation energy requirements.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Coronary Disease; Defi | 1997 |
Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events?
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Amb | 1999 |
Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac | 1999 |
Heart rate dynamics at the onset of ventricular tachyarrhythmias as retrieved from implantable cardioverter-defibrillators in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Coronary Disease; Defibrillators, Implant | 2000 |
Comparison of the long-term efficacy of implantable defibrillators and sotalol for documented spontaneous sustained ventricular tachyarrhythmias secondary to coronary artery disease.
Topics: Aged; Anti-Arrhythmia Agents; Coronary Disease; Defibrillators, Implantable; Female; Humans; Male; M | 1999 |
Amiodarone to prevent recurrence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Humans; Hypertrophy, Left | 2000 |
Preconditioning attenuates the shortening of recovery during coronary occlusion in isolated rabbit hearts with D-sotalol-induced long QT intervals.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Electrophysiology; Female; In | 2002 |
Involvement of beta adrenergic receptors in decrease of myocardial pH during ischemia.
Topics: Animals; Coronary Disease; Coronary Vessels; Dogs; Female; Hydrogen-Ion Concentration; Isoproterenol | 1979 |
Influence of the adrenal medulla on cardiac rhythm disturbances following acute coronary artery occlusions.
Topics: Adrenal Medulla; Animals; Arrhythmias, Cardiac; Cats; Coronary Disease; Epinephrine; Female; Lidocai | 1975 |
Hemodynamic effects of d-sotalol in acute ischemic heart failure in dogs.
Topics: Acute Disease; Animals; Coronary Disease; Diastole; Disease Models, Animal; Dogs; Dose-Response Rela | 1992 |
Comparative antifibrillatory effects of d- and dl-sotalol in normal and ischaemic ventricular muscle of the cat.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Cats; Coronary Disease; Female; Heart; | 1990 |
Effects of the new class-III antiarrhythmic drug D-sotalol on contractile function of postischemic myocardium.
Topics: Animals; Coronary Disease; Heart Rate; Hemodynamics; Male; Myocardial Contraction; Rats; Rats, Inbre | 1991 |
Effects of simulated ischaemia on the electrical activity of ventricular myocardium in the presence of antiarrhythmic drugs.
Topics: Action Potentials; Animals; Coronary Disease; Electric Stimulation; Female; Heart; Heart Conduction | 1991 |
Sotalol in patients with life-threatening ventricular tachyarrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Angiography; Coronary Disease; Electric Stimulation; E | 1990 |
Effects of antiarrhythmic agents classified as class III group on ischaemia-induced myocardial damage in canine hearts.
Topics: Acetylglucosaminidase; Amiodarone; Anesthesia; Animals; Anti-Arrhythmia Agents; Blood Pressure; Coro | 1990 |
Attenuation of the rise in extracellular potassium concentration during myocardial ischaemia by d.l-sotalol and d-sotalol.
Topics: Action Potentials; Animals; Coronary Disease; Extracellular Space; Heart; In Vitro Techniques; Membr | 1990 |
Long-term sotalol therapy in patients with ventricular arrhythmias.
Topics: Aged; Angina Pectoris; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomyopathy, Dilated; | 1986 |
Effects of nicorandil and other antianginal drugs on myocardial pH in the ischemic dog heart.
Topics: Acidosis; Animals; Coronary Disease; Diltiazem; Dogs; Hydrogen-Ion Concentration; In Vitro Technique | 1987 |
Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors.
Topics: Adolescent; Adult; Cardiomyopathy, Dilated; Child; Child, Preschool; Coronary Disease; Heart Failure | 1989 |
[Therapeutic indications for sotalol 160 mg].
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomyopathy, Dil | 1985 |
The differential response of normal and ischaemic Purkinje fibres to clofilium, d-sotalol and bretylium.
Topics: Animals; Anti-Arrhythmia Agents; Bretylium Compounds; Coronary Disease; Dogs; Heart Conduction Syste | 1989 |
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Topics: Aged; Coronary Disease; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1989 |
Beta-blocking agents and plasma lipids: an update.
Topics: 1-Propanol; Adrenergic beta-Antagonists; Atenolol; Cholesterol, LDL; Coronary Disease; Humans; Hyper | 1987 |
Prevention of ventricular fibrillation by metoprolol in a pig model of acute myocardial ischaemia: absence of a major arrhythmogenic role for cyclic AMP.
Topics: Acute Disease; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Blood Pressure; Coronary Circu | 1986 |
The effect of sotalol on exercise-induced ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Cardiomyopathies; Coronary Disease; D | 1988 |
Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Dogs; Female; Heart Conduct | 1987 |
[Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography | 1987 |
Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Death, Sudden; Diseas | 1985 |
The influence of acute myocardial ischaemia on the class III antiarrhythmic action of sotalol.
Topics: Action Potentials; Acute Disease; Animals; Anti-Arrhythmia Agents; Coronary Disease; Electric Stimul | 1985 |
Interaction of the effects of hypoxia, substrate depletion, acidosis and hyperkalaemia on the class III antiarrhythmic properties of sotalol.
Topics: Acidosis; Action Potentials; Acute Disease; Animals; Anti-Arrhythmia Agents; Coronary Disease; Cultu | 1985 |
Early arrhythmias following experimental coronary occlusion in conscious dogs and their modification by beta-adrenoceptor blocking drugs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Pressure; Consciousn | 1973 |
Protective effect of beta adrenoceptor blockade in experimental coronary occlusion in conscious dogs.
Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Animals; Coronary Disease; Disease Models | 1972 |